Skip to main content
. 2017 Apr 11;8(3):573–586. doi: 10.1007/s13300-017-0255-6

Table 1.

Baseline characteristics

Baseline characteristics Open-access phase intervention participants (N = 139)
Age (years) 59.3 ± 9.6 [33, 77]
Weight (kg) 97 ± 20 [51, 170]
Body mass index (kg/m2) 33.1 ± 6.0 [18.8, 54.1]
Duration of diabetes (years) 17 ± 8 [2, 43]
Duration of insulin use (years) 9 ± 6 [0, 40]
Screening HbA1c
  mmol/mol 71.8 ± 10.5 [59, 103]
  % 8.72 ± 0.96 [7.5, 11.6]
Self-reported blood glucose frequency per day 3.6 ± 1.29 [1, 10]
Insulin (total daily dose)
  Basal units (n = 124) 38.0 ± 21.0
  Bolus units (n = 115) 51.7 ± 30.4
  CSII units (n = 5) 56.5 ± 39.5
Open-access phase intervention participants
N (%)
Gender (male) 88 (63%)
Ethnicity
  White 134 (96%)
  Black 1 (1%)
  Asian/Pacific Islander 1 (1%)
  Other 3 (2%)
Diabetes management
  Insulin pen device 130 (94%)
  CSII 8 (6%)
  Insulin syringe 1 (1%)
Previous CGM use 10 (7%)
Employment status
  Employed (n = 136) 56 (41%)
  Not employed/retired/other (n = 136) 80 (59%)
Insulin management training
  <1 year ago 41 (29%)
  >1 year ago 93 (67%)
Carbohydrate counting training
  <1 year ago 40 (29%)
  >1 year ago 49 (35%)
Bolus dose titration
  Based on meal content (n = 138) 89 (64%)
  Based on current glucose level (n = 138) 108 (78%)
  Using sliding scale (n = 138) 53 (38%)

Values in table are presented as the mean ± standard deviation (SD) with the range in square brackets or as the number with the percentage in parenthesis, as appropriate

CGM Continuous glucose monitoring, CSII continuous subcutaneous insulin infusion, HbA1c glycated hemoglobin